Literature DB >> 8790930

Marked hepatotoxicity associated with losartan treatment.

B Nygaard1, S Strandgaard.   

Abstract

Losartan represent a novel approach in the treatment of hypertension. Clinical trials have reported a very low incidence of side effects. We describe two patients who developed increases in alanine/aspartate amino transferase of 8 and 15 times the upper normal limit, as well as thoracic pain, after a short time of treatment with losartan. The increase resolved after discontinuing losartan treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8790930     DOI: 10.3109/08037059609062128

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  7 in total

1.  Drug points: prolonged cholestasis associated with irbesartan.

Authors:  R Hariraj; E Stoner; S Jader; D M Preston
Journal:  BMJ       Date:  2000-09-02

2.  No association between losartan use and acute pancreatitis in hypertensive patients.

Authors:  Shih-Wei Lai; Hsien-Feng Lin; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Eur J Hosp Pharm       Date:  2016-05-05

3.  Losartan-induced Ischemic Hepatocellular Hepatotoxicity: A Case Report and Literature Review.

Authors:  Moh'd Z Al-Halawani; Mohammad Thawabi; Fady Asslo; Hamid Shaaban; Fayez Shamoon; Walid J Baddoura
Journal:  J Family Med Prim Care       Date:  2014-07

4.  Angiotensin II protects primary rat hepatocytes against bile salt-induced apoptosis.

Authors:  Golnar Karimian; Manon Buist-Homan; Bojana Mikus; Robert H Henning; Klaas Nico Faber; Han Moshage
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

5.  Telmisartan/hydrochlorothiazide-induced hepatotoxicity.

Authors:  Marco Lorena; Aldo Autolitano; Giovanni Natale; Federica Uberti; Fabrizio Vitali; Camillo Schiantarelli; Nicola Lucio Liberato
Journal:  Arch Med Sci       Date:  2015-08-11       Impact factor: 3.318

6.  Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report.

Authors:  Dae Hwa Park; Gee Young Yun; Hyuk Soo Eun; Jong Seok Joo; Ju Seok Kim; Sun Hyung Kang; Hee Seok Moon; Eaum Seok Lee; Byung Seok Lee; Kyung Hee Kim; Seok Hyun Kim
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

7.  Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.

Authors:  Gyu Chul Oh; Kwon Wook Joo; Myung-A Kim; Dong-Ju Choi; Yoon Jun Kim; Hae-Young Lee
Journal:  Drug Des Devel Ther       Date:  2020-04-03       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.